-
公开(公告)号：US20120310366A1
公开(公告)日：2012-12-06
申请号：US13489173
申请日：2012-06-05
申请人： Ping Li , Jeffrey C. Marx , William F. McKay
发明人： Ping Li , Jeffrey C. Marx , William F. McKay
IPC分类号： A61F2/28
CPC分类号： A61K31/366 , A61F2002/2839 , A61F2002/30677 , A61K31/22 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/47 , A61K31/505 , A61K33/42 , A61K47/22
摘要： Implantable medical devices and methods are provided that have one or more statins disposed therein. The medical devices may be implanted at near or in a bone defect to enhance bone growth. In some embodiments, the medical device provided allows for sustain release of the statin and facilitates bone formation and repair of the fracture site.
摘要翻译： 提供了植入式医疗装置和方法，其中设置有一个或多个他汀类药物。 医疗装置可以植入在骨缺损附近或骨缺损处以增强骨生长。 在一些实施方案中，所提供的医疗装置允许持续释放他汀类并促进骨形成部位的骨形成和修复。
-
2.发明申请COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE AND BUPIVACAINE TO A TARGET TISSUE SITE 有权将CLONIDINE和BUPIVACAINE递送至目标组织网站的组合物和方法公开(公告)号：US20120142649A1
公开(公告)日：2012-06-07
申请号：US13310240
申请日：2011-12-02
申请人： Jonathan K. Gray , Jeffrey C. Marx , William F. McKay , Josee Roy , Danielle L. Clay , Jared T. Wilsey , John Myers Zanella
发明人： Jonathan K. Gray , Jeffrey C. Marx , William F. McKay , Josee Roy , Danielle L. Clay , Jared T. Wilsey , John Myers Zanella
IPC分类号： A61K31/56 , A61P29/00 , A61K31/445
CPC分类号： A61K9/0024 , A61K31/167 , A61K31/4168 , A61K31/445 , A61K47/34 , A61K2300/00
摘要： Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release bupivacaine or lidocaine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer.
摘要翻译： 提供长时间有效的疼痛治疗。 通过施用有效量的即时释放布比卡因或利多卡因和持续释放的可乐定，可以缓解由不同来源引起的疼痛，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位，狭窄 ，造成背痛和关节疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天或更长。
-
3.发明授权Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use 有权包含用于治疗神经元损伤的生物膜密封剂的组合物和使用方法公开(公告)号：US08945623B2
公开(公告)日：2015-02-03
申请号：US11418152
申请日：2006-05-03
申请人： Josee Roy , William F. McKay , Jeffrey C. Marx
发明人： Josee Roy , William F. McKay , Jeffrey C. Marx
IPC分类号： A61K38/20 , A61K38/18 , A61K38/11 , A61K38/05 , A61K31/65 , A61K31/56 , A61K9/14 , A61K9/00 , A61K33/06 , A61K47/10
CPC分类号： A61K33/06 , A61K9/0019 , A61K31/56 , A61K31/65 , A61K31/765 , A61K47/10
摘要： The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
摘要翻译： 本发明提供用于治疗神经元损伤的组合物，试剂盒和方法。 在一个实施方案中，组合物包含生物膜密封剂，例如PEG，以及生物活性剂，例如镁化合物。 静脉内给药，肌内给药，鞘内给药，皮下给药，硬膜外给药，胃肠外给药，直接施用于病理状况的部位或其附近的生物膜密封剂和/或生物活性剂，以及任何 其组合。 或者，生物膜密封剂和/或生物活性剂可以从泵或植入物递送。
-
公开(公告)号：US08916611B2
公开(公告)日：2014-12-23
申请号：US11413363
申请日：2006-04-28
申请人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx
发明人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx
IPC分类号： A61K31/185 , A61K31/115 , A61K31/045 , A61K31/737 , A61K31/485 , A61K31/655 , A61K31/56 , A61K38/16 , A61K31/11 , A61K31/225 , A61K36/31 , A61K38/48 , A61K31/125 , A61K36/9066 , A61K31/4709
CPC分类号： A61K38/4893 , A61K31/11 , A61K31/125 , A61K31/225 , A61K31/4709 , A61K31/485 , A61K31/496 , A61K31/5415 , A61K31/55 , A61K31/56 , A61K31/65 , A61K31/655 , A61K31/737 , A61K33/02 , A61K36/31 , A61K36/9066 , A61K38/168 , A61K38/4886 , C12Y304/24069
摘要： The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
摘要翻译： 本发明提供了一种通过施用破坏椎间盘中的神经元和/或血管元件（通常是退化的椎间盘）的治疗剂来减轻椎间盘突出症的方法。 磁盘中的神经元元件的破坏包括破坏神经末梢，而不会显着影响神经的中枢体，抑制神经末梢的激活，并抑制神经末梢进入椎间盘的生长。 血管元件的破坏包括使血管延伸部从圆盘缩回，或抑制这种延伸部的形成。 治疗剂可以通过体内泵，推注或贮库局部给药，或者可以全身给药。
-
公开(公告)号：US20120258999A1
公开(公告)日：2012-10-11
申请号：US13369419
申请日：2012-02-09
申请人： JEFFREY C. MARX
发明人： JEFFREY C. MARX
IPC分类号： A61K31/713 , A61P29/00
CPC分类号： A61K9/0024 , A61K47/34
摘要： The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1 IL6 and other pro-inflammatory cytokines.
摘要翻译： 本发明涉及使用靶向TNFα，IL1 IL6和其它促炎细胞因子的小干扰RNA（siRNA）分子治疗受试者的炎症和疼痛的试剂，方法和系统。
-
6.发明授权Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2 有权诱导骨沉积和成熟的方法，包括LMP-1和BMP-2的共同治疗方案公开(公告)号：US07504374B2
公开(公告)日：2009-03-17
申请号：US11385612
申请日：2006-03-21
CPC分类号： A61K38/1709 , A61K38/1875 , A61K2300/00
摘要： The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.
摘要翻译： 本发明涉及用于治疗受损骨患者的方法和组合物。 具体地，本发明涉及包括LIM矿化蛋白（特别是LMP-1）的小分子和肽模拟物的组合治疗策略，以克服BMP-2治疗剂的剂量相关翻译屏障。
-
公开(公告)号：US20080097229A1
公开(公告)日：2008-04-24
申请号：US11511701
申请日：2006-08-29
申请人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx , Sean M. Haddock
发明人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx , Sean M. Haddock
CPC分类号： A61L27/50 , A61F2002/30075 , A61F2002/444 , A61F2210/0061 , A61L27/14 , A61L2430/38
摘要： Early treatment for a degenerated disc includes identifying a non-ruptured, dehydrated disc. A hygroscopic agent is then selected. This agent should pull water towards itself and have a hygroscopic compound with a molecular weight of at least 400 Daltons. Additionally, it may be desirable to selected hygroscopic compounds that are anionic or electrically neutral. The hygroscopic agent is then injected into the nucleus pulposus of the disc without any prior removal of the nucleus pulposus material. Because the surrounding disc structure allows for the passive diffusion of water into the nucleus pulposus, the hygroscopic agent will draw water into the nucleus pulposus, thus promoting tissue hydration within the disc. The hygroscopic agent may also include a biological agent and/or an imaging agent.
摘要翻译： 退化椎间盘的早期治疗包括鉴定未破裂的脱水椎间盘。 然后选择吸湿剂。 该试剂应将水拉向自身并具有分子量至少为400道尔顿的吸湿性化合物。 另外，可能需要选择阴离子或电中性的吸湿化合物。 然后将吸湿剂注射到盘的髓核中，而无需先前去除髓核成分材料。 因为周围的圆盘结构允许水被钝化地扩散到髓核中，吸湿剂会将水吸入髓核，从而促进椎间盘内的组织水合作用。 吸湿剂还可以包括生物制剂和/或成像剂。
-
公开(公告)号：US09789161B2
公开(公告)日：2017-10-17
申请号：US11414689
申请日：2006-04-28
申请人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx
发明人： Josee Roy , Susan J. Drapeau , Jeffrey C. Marx
CPC分类号： A61K38/1825 , A61K38/185 , A61K38/1858 , A61K38/2093 , A61K38/212
摘要： The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
-
9.发明授权Compositions and methods for delivering clonidine and bupivacaine to a target tissue site 有权将可乐定和布比卡因递送至目标组织部位的组合物和方法公开(公告)号：US08623396B2
公开(公告)日：2014-01-07
申请号：US13310240
申请日：2011-12-02
申请人： Jonathan K. Gray , Jeffrey C. Marx , William F. McKay , Josee Roy , Danielle L. Clay , Jared T. Wilsey , John Myers Zanella
发明人： Jonathan K. Gray , Jeffrey C. Marx , William F. McKay , Josee Roy , Danielle L. Clay , Jared T. Wilsey , John Myers Zanella
CPC分类号： A61K9/0024 , A61K31/167 , A61K31/4168 , A61K31/445 , A61K47/34 , A61K2300/00
摘要： Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release bupivacaine or lidocaine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer.
摘要翻译： 提供长时间有效的疼痛治疗。 通过施用有效量的即时释放布比卡因或利多卡因和持续释放的可乐定，可以缓解由不同来源引起的疼痛，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位，狭窄 ，造成背痛和关节疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天或更长。
-
公开(公告)号：US08252738B2
公开(公告)日：2012-08-28
申请号：US11875267
申请日：2007-10-19
CPC分类号： A61L27/54 , A61F2002/2817 , A61F2002/4445 , A61F2002/445 , A61K9/0024 , A61K38/1875 , A61L2300/252 , A61L2300/258 , A61L2300/414 , C12N5/0602 , C12N2501/105 , C12N2501/155 , C12N2501/165 , C12N2501/60 , C12N2501/998 , C12N2510/00 , A61K2300/00
摘要： Methods of changing a phenotype of a cell are provided. The methods comprise increasing an amount of an amino acid sequence which is at least 70% identical to an amino acid sequence encoding an LMP protein or a fragment thereof in a cell. The cells may be contacted by either a composition comprising a nucleic acid sequence encoding the amino acid sequence which is at least 70% identical to the amino acid sequence encoding an LMP or its fragment or by a composition comprising acid sequence which is at least 70% identical to the amino acid sequence encoding an LMP or its fragment or any combination thereof. The cells may be contacted either in vivo or ex-vivo.
摘要翻译： 提供改变细胞表型的方法。 所述方法包括增加与细胞中编码LMP蛋白或其片段的氨基酸序列至少70％相同的氨基酸序列的量。 细胞可以由包含编码与编码LMP或其片段的氨基酸序列至少70％相同的氨基酸序列的核酸序列或包含至少70％的酸序列的组合物的组合物接触， 与编码LMP或其片段的氨基酸序列或其任何组合相同。 细胞可以在体内或体外接触。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.02 秒)